16.22

1.88% -0.31

After Hours: 16.22

Enliven Therapeutics Inc (ELVN)

Overview News Price History Option Chain Financials Discussions Forecast

Enliven Therapeutics Inc stock is traded at $16.22, with a volume of 282.23K. It is down -1.88% in the last 24 hours and down -23.06% over the past month. Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Previous Close:

$16.53

Open:

$16.15

24h Volume:

282.23K

Relative Volume:

1.08

Market Cap:

$842.39M

Revenue:

Net Income/Loss:

$-85.21M

P/E Ratio:

-8.582

EPS:

-1.89

Net Cash Flow:

$-68.53M

1W Performance:

-5.64%

1M Performance:

-23.06%

6M Performance:

-43.82%

1Y Performance:

-6.13%

1-Day Range:

$15.44

$16.82

1-Week Range:

$15.44

$18.14

52-Week Range:

$13.30

$30.03

Enliven Therapeutics Inc Stock (ELVN) Company Profile

Name

Enliven Therapeutics Inc

Sector

Healthcare (1155)

Industry

Biotechnology (677)

Phone

720-647-8519

Address

6200 LOOKOUT ROAD, BOULDER

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

ELVN's Discussions on Twitter

Compare ELVN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ELVN Enliven Therapeutics Inc	16.22	842.39M	0	-85.21M	-68.53M	-1.89
VRTX Vertex Pharmaceuticals Inc	477.52	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	561.49	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	595.70	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	232.75	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	229.22	26.16B	3.81B	-644.79M	-669.77M	-6.24

Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-13-24	Initiated	BTIG Research	Buy
Sep-09-24	Initiated	H.C. Wainwright	Buy
Jun-11-24	Initiated	Robert W. Baird	Outperform
Apr-09-24	Initiated	Mizuho	Buy
Mar-29-23	Initiated	Jefferies	Buy

Enliven Therapeutics Inc Stock (ELVN) Latest News

Apr 20, 2025

Geode Capital Management LLC Acquires 12,510 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Apr 20, 2025

Apr 15, 2025

(ELVN) Trading Report - news.stocktradersdaily.com

Apr 15, 2025

Apr 13, 2025

Vanguard Group Inc. Purchases 55,283 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Apr 13, 2025

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Boosted by Wellington Management Group LLP - Defense World

Apr 13, 2025

Apr 11, 2025

KLP Kapitalforvaltning AS Makes New $97,000 Investment in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Apr 11, 2025

Apr 10, 2025

Ratios Revealed: Decoding Enliven Therapeutics Inc (ELVN)’s Financial Health - DWinneX

Apr 10, 2025

Corebridge Financial Inc. Trims Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Apr 10, 2025

Apr 09, 2025

Enliven Therapeutics COO Anish Patel sells shares worth $120,268 By Investing.com - Investing.com India

Apr 09, 2025

Enliven Therapeutics COO Anish Patel sells shares worth $120,268 - Investing.com Australia

Apr 09, 2025

Apr 06, 2025

Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High? - MSN

Apr 06, 2025

Apr 02, 2025

Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting - StreetInsider

Apr 02, 2025

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4.9% After Insider Selling - Defense World

Apr 02, 2025

Apr 01, 2025

Enliven Therapeutics CFO Benjamin Hohl sells $69,320 in stock By Investing.com - Investing.com UK

Apr 01, 2025

Mar 31, 2025

Enliven Therapeutics CFO Benjamin Hohl sells $69,320 in stock - Investing.com

Mar 31, 2025

Mar 30, 2025

Where are the Opportunities in (ELVN) - news.stocktradersdaily.com

Mar 30, 2025

Swiss National Bank Increases Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Mar 30, 2025

Mar 27, 2025

Enliven Therapeutics CFO sells $22,504 in stock By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 26, 2025

Enliven Therapeutics CFO sells $22,504 in stock - Investing.com India

Mar 26, 2025

Mar 25, 2025

Charles Schwab Investment Management Inc. Grows Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Mar 25, 2025

Mar 23, 2025

HC Wainwright Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock - Defense World

Mar 23, 2025

Mar 22, 2025

Bank of New York Mellon Corp Sells 828 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Mar 22, 2025

Mar 21, 2025

Enliven Therapeutics chief scientific officer sells $257,575 in stock By Investing.com - Investing.com Canada

Mar 21, 2025

Enliven Therapeutics chief scientific officer sells $257,575 in stock - Investing.com India

Mar 21, 2025

Mar 20, 2025

Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory - Marketscreener.com

Mar 20, 2025

Enliven Therapeutics CEO Samuel Kintz sells $260,320 in stock By Investing.com - Investing.com UK

Mar 19, 2025

Mar 15, 2025

Decoding Enliven Therapeutics Inc (ELVN): A Strategic SWOT Insig - GuruFocus.com

Mar 15, 2025

Mar 14, 2025

Enliven grew fourth-quarter R&D spending with trials underway - BizWest

Mar 14, 2025

Enliven Therapeutics Stock (ELVN): Promising Advances in Oncology Pipeline - Value The Markets

Mar 14, 2025

Enliven Therapeutics Reports 2024 Financial Results - TipRanks

Mar 14, 2025

Mar 13, 2025

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - Citizentribune

Mar 13, 2025